Which tumors secrete erythropoietin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Erythropoietin-Secreting Tumors

The tumors most commonly associated with erythropoietin (EPO) secretion are renal cell carcinoma, cerebellar hemangioblastoma, hepatocellular carcinoma (hepatoma), and uterine leiomyomas.

Primary EPO-Secreting Tumors

Renal Cell Carcinoma

Renal adenocarcinoma is the classic EPO-secreting malignancy, with 1-5% of cases presenting with secondary polycythemia 1. The tumor cells themselves—specifically those of tubular epithelial origin—constitutively produce EPO, as demonstrated by in situ hybridization showing EPO mRNA within the malignant cells 1. This production is constitutive and not induced by hypoxia or other stimuli 2. The EPO gene shows no rearrangement in these tumors; rather, the malignant cells aberrantly express normal EPO 2, 1.

Cerebellar Hemangioblastoma

Capillary hemangioblastomas are well-documented EPO-producing tumors that frequently cause secondary polycythemia 3. Immunohistochemical studies demonstrate EPO within scattered stromal cells among the tumor architecture 3. These tumors harbor cells that both contain and likely produce EPO or substances with similar antigenic properties 3.

Hepatocellular Carcinoma

Hepatomas are recognized as EPO-secreting tumors causing paraneoplastic erythrocytosis 2. The liver normally produces EPO during fetal development, and hepatocellular carcinomas can reactivate this embryonic function.

Uterine Leiomyomas

Although benign, uterine fibroids can produce EPO and cause secondary erythrocytosis in rare cases 4, 5. This condition, termed myomatous erythrocytosis syndrome (MES), shows a positive correlation between tumor size and degree of erythrocytosis 5. Surgical resection results in normalization of hemoglobin levels 4.

Additional Tumors with EPO Production

Wilms tumors, hepatoblastomas, and various pediatric solid tumors (neuroblastomas, Ewing's sarcoma, medulloblastomas, astrocytomas, ependymomas, and rhabdomyosarcomas) express both EPO and functional EPO receptors 6. In these tumors, EPO expression is hypoxia-inducible and appears to promote tumor cell survival through antiapoptotic pathways and angiogenesis rather than causing systemic erythrocytosis 6.

Clinical Recognition

Key Diagnostic Features:

  • Elevated hemoglobin and hematocrit disproportionate to clinical status
  • Elevated serum EPO levels (measured by radioimmunoassay)
  • Absence of other causes of polycythemia (hypoxia, smoking, chronic lung disease, renal disease)
  • Normalization of blood counts following tumor resection

Important Caveats:

The presence of polycythemia with a solid tumor should prompt measurement of serum EPO levels. However, not all tumors expressing EPO cause systemic erythrocytosis—pediatric tumors express EPO primarily for autocrine/paracrine effects on tumor survival and angiogenesis rather than erythropoiesis 6.

Tumor resection remains the definitive treatment for paraneoplastic polycythemia, with resolution of erythrocytosis confirming the diagnosis 4, 2, 1.

Related Questions

Which cancers can cause elevated hematocrit and hemoglobin (erythrocytosis) in a 54‑year‑old woman?
What is the recommended evaluation and management for a patient with persistently elevated red blood cell count (erythrocytosis) who does not snore, does not smoke, and is not taking any medications?
Which hematologic malignancies are associated with erythrocytosis, elevated hematocrit, and increased hemoglobin?
What is Myomatous erythrocytosis syndrome (MES) in a 54‑year‑old woman with unexplained elevated hemoglobin/hematocrit and large uterine leiomyomas?
What are the indications, dosing regimens, contraindications, and adverse effects of alvimopan and methyl‑naltrexone (extended‑release naltrexone)?
Can you define and explain data types, food hygiene and safety practices, adolescent health services, the agency overseeing GIFTS, types of pollution and how deforestation causes land pollution, sensitivity, specificity, and positive predictive value, the CHPS program and its leadership, Ghana's health system structure, occupational health hazards and their health implications, urbanization's social and health problems, how to conduct a cohort study, the relationship between poverty and health, and common measures of fertility?
Can Depakote (valproic acid) cause an increased pulse (tachycardia)?
What are the differential diagnoses and pertinent questions to ask for a patient presenting with loss of visual field in the left eye?
Can you compare demographic transition theory with logistic growth and define sensitivity, specificity, and positive predictive value, list antenatal non‑communicable disease services, WHO‑recommended iron‑folic acid supplementation duration, investigations at the antenatal booking visit, signs of rat infestation, the meaning and staff of Community‑Based Health Planning Services (CHPS), benefits of school feeding programs, social implications of teenage pregnancy, diseases excluded from NHIS pre‑employment assessment, components of periodic workplace health assessments, health and economic impacts of festivals, and the services a community medical officer should provide (antenatal care, immunizations, family planning, cohort study)?
For a patient who has adverse reactions to Repatha (alirocumab), ezetimibe, and statins, what other lipid‑lowering treatment options are available?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.